Catalog No.: PC-49255Not For Human Use, Lab Use Only.
MIN-102 (Leriglitazone) is a novel brain penetrant, selective and orally bioavailable PPARγ agonist with a potential best-in-class profile indicated for CNS diseases.
MIN-102 (Leriglitazone) is a novel brain penetrant, selective and orally bioavailable PPARγ agonist with a potential best-in-class profile indicated for CNS diseases.
MIN-102 (Leriglitazone) increases frataxin levels and mitochondrial markers in FRDA models.
MIN-102 (Leriglitazone) protects from neurodegeneration by improving mitochondrial function.
MIN-102 (Leriglitazone) prevents lipid droplets formation in frataxin-deficient cardiomyocytes.
MIN-102 (Leriglitazone) rescues the motor function deficit of the YG8sR mice.
MIN-102 (Leriglitazone) emerges as a potential therapeutic agent for Friedreich Ataxia.
